Immuno-Oncology | Specialty

FDA Approves Atezolizumab in Bladder Cancer

May 18th 2016

The FDA granted the PD-L1 inhibitor atezolizumab (Tecentriq) an accelerated approval as a treatment for patients with locally advanced or metastatic urothelial carcinoma (mUC) whose disease progressed during or after platinum-based chemotherapy, or within 12 months of receiving platinum-based chemotherapy, either before or after surgery.

FDA Approves Nivolumab for Hodgkin Lymphoma

May 17th 2016

The FDA approved nivolumab (Opdivo) for the treatment of patients with classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation and posttransplantation brentuximab vedotin (Adcetris).

Oncolytic Poliovirus Receives Breakthrough Designation for Glioblastoma

May 16th 2016

The recombinant oncolytic poliovirus PVS-RIPO has received breakthrough therapy designation from the FDA as a potential treatment for patients with recurrent glioblastoma multiforme.

Expert Discusses Promise of CRS-207 Vaccine in Mesothelioma

May 16th 2016

Thierry M. Jahan, MD, discusses a study looking at the investigational cancer vaccine CRS-207 and its potential in mesothelioma.

PD-1 Expression on Monocytes Potential Immunotherapy Biomarker in RCC

May 13th 2016

Mohammed Haseebuddin, MD, discusses results of a study which demonstrated that elevated preoperative classical monocyte PD-1 mean fluorescence intensity level and lower CM was linked to poor survival in patients with clear cell renal cell carcinoma, as well as the challenges with using PD-1 as a biomarker in these patients.

Further Steps Needed to Unleash Full Potential of Immunotherapy in Lung Cancer

May 13th 2016

John Haanen, MD, PhD, discusses why the best combination regimens and the ideal patient population for immunotherapy treatments in lung cancer are still largely unknown.

Dreicer Discusses Pivotal Trial, Excitement With Atezolizumab in mUC

May 12th 2016

Robert Dreicer, MD, provides insight on the IMvigor 210 study and how atezolizumab will dramatically change the treatment paradigm for patients with metastatic urothelial carcinoma, who have a severe unmet need.

Krishna Vanaja Donkena on Using Immune Markers to Predict Survival in Bladder Cancer

May 12th 2016

Krishna Vanaja Donkena, PhD, Assistant Professor of Biochemistry and Molecular Biology, Center for Individualized Medicine, Mayo Clinic, discusses using immune and checkpoint markers to predict cancer-specific survival in bladder cancer.

Nivolumab/Ipilimumab Combo Approved in Europe for Advanced Melanoma

May 12th 2016

The European Commission has approved the combination of ipilimumab and nivolumab as a treatment for patients with unresectable or metastatic melanoma regardless of BRAF status.

Liquid Imiquimod Formulation May Induce Immune Response in Bladder Cancer

May 11th 2016

TMX-101 (Vesimune), a liquid formulation of the toll-like receptor 7 agonist imiquimod, appeared safe and demonstrated preliminary clinical activity, including the potential to induce an immune response, in patients with non-muscle invasive bladder cancer.

Molecular Testing, New Biomarkers on Horizon for Immunotherapy in RCC

May 11th 2016

Mark Ball, MD, discusses the clinical, pathological, and genomic profiles of exceptional responders to antiâ€“PD-1 therapy in renal cell carcinoma, the future of immunotherapy, and what significance genomic testing may hold.

Dr. Infante on AM0010 in Patients With RCC

May 11th 2016

Jeff R. Infante, MD, director, Drug Development Program, Sarah Cannon Research Institute, discusses a phase I study of the novel immunotherapy agent AM0010 and its early promise in patients with renal cell carcinoma.

Ribas Shares Emerging Advances With Immunotherapy in Melanoma

May 10th 2016

Antoni Ribas, MD, PhD, shares exciting clinical trial results of immunotherapy agents in patients with melanoma, as well as what the future holds for the field.

Dr. Sharpless on Managing Toxicities With Nivolumab and Ipilimumab in Melanoma

May 5th 2016

Norman E. Sharpless, MD, professor of Medicine and Genetics, chair, the University of North Carolina (UNC) Lineberger Comprehensive Cancer Center, UNC School of Medicine, discusses how oncologists can best manage toxicities associated with the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the treatment of patients with melanoma.

Expert Discusses Latest Findings With Nivolumab/Ipilimumab Combo in Melanoma

April 29th 2016

Patrick Ott, MD, PhD, discusses toxicity management and patient selection considerations required with the combination of nivolumab (Opdivo)/ipilimumab (Yervoy), and its role in BRAF-mutant melanoma.

Radium-223 May Enhance Immune Response With Sipuleucel-T in mCRPC

April 26th 2016

Jong Chul Park, MD, discusses the potential synergy of radium-223 and sipuleucel-T, which is being investigated in a clinical trial as a potential treatment for patients with metastatic castration-resistant prostate cancer.

FDA Grants Nivolumab Breakthrough Designation for Head and Neck Cancer

April 25th 2016

The FDA has granted a breakthrough therapy designation to nivolumab as a single-agent treatment for patients with recurrent or metastatic squamous cell carcinoma of the head and neck following a platinum-based therapy.

Dr. Kelly on the JAVELIN Solid Tumor Trial

April 22nd 2016

Karen Kelly, MD, associate director for Clinical Research, Jennifer Rene Harmon Tegley and Elizabeth Erica Harmon Endowed Chair in Cancer Clinical Research, professor of Medicine, UC Davis Comprehensive Cancer Center, discusses the results of the phase Ib JAVELIN Solid Tumor Trial.

Expert Hopes Immunotherapy Combos Will Deliver Durable Remissions in RCC

April 21st 2016

Robert Figlin, MD, discusses some emerging agents and ongoing trials that could transform the treatment landscape of renal cell carcinoma.

Twitter Becomes Forum for Opdivo Coverage Dispute

April 20th 2016

Social media has become an outlet for expressing frustration with the struggle to get insurance approvals for oncology tests and treatments.